BLATOPICALGEL
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
NEXOBRID (anacaulase-bcdb) by MediWound is eschar. First approved in 2022.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXOBRID (anacaulase-bcdb) is a topical gel biologic approved by FDA in December 2022 for enzymatic debridement of burn wounds. It works by dissolving necrotic tissue (eschar), though the specific active components have not been fully characterized. The product represents a novel enzymatic approach to wound management in acute burn care.
Peak
Product is in peak commercial phase post-launch; team size and resource allocation likely established but trajectory depends on adoption in specialized burn centers.
Mechanism of Action
eschar. The specific components responsible for this effect have not been identified.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns
Started May 2015
175 enrolled
Thermal Burns
A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care
Started May 2015
145 enrolled
Thermal Burns
Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries
Thermal Burn
Career Relevance
NEXOBRID represents a specialized, niche-market opportunity in burn surgery rather than a mass-market therapeutic. Career roles will focus on adoption among burn centers, surgeon education, and establishing standard-of-care positioning in a concentrated provider base.
Worked on NEXOBRID at MediWound? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.